Teva Acquires Labrys Biologics For As Much As $825M

June 5, 2014 | Teva Pharmaceutical Industries acquired Labrys Biologics for up to $825 million, according to Globes. The leading Israeli pharmaceutical company reportedly payed Labrys $200 million in cash upfront and will pay up to $625 million in contingent payments following launch.

Labrys Biologics is a private biotechnological company focused on treatments for chronic and episodic migraine headaches. The acquisition of the company aids in Teva’s goal of becoming a world leader in pain by the year 2020.